UNSPSC 51334103: Lurasidone

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C28H36N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22IC88528T, chemically known as (3ar,4s,7r,7as)-2-((1r,2r)-2-(4-(1,2-benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2h-isoindole-1,3-dione but generally known as lurasidone, which bears US NIH Compound Identifier 213046.

UNSPSC 51334103 Lurasidone (Commodity) appears in recent state and local procurement as part of broader pharmaceutical procurement activity, though the available opportunities show limited direct purchasing of this specific antipsychotic medication. State and local governments use this code to procure pharmaceutical products through multiple channels: direct county health procurement, state pharmacy benefit program development, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The work involves establishing supply contracts with pharmaceutical manufacturers and wholesalers, negotiating pricing structures, managing NDC-based product specifications, and ensuring compliance with FDA requirements, cGMP standards, and the Drug Supply Chain Security Act.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems with annual quantities and quarterly deliveries, signaling county-level health procurement infrastructure. Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, indicating state-level pharmaceutical supply chain strategy development. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, establishing contracts effective July 1, 2026, with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and requiring vendors to certify cGMP compliance and maintain relationships with at least two wholesalers. The MMCAP procurement weights price competitiveness at 75 percent and imposes a 3 percent administrative fee on all contract purchases. No opportunities in the source name lurasidone specifically; the code's recent activity reflects general pharmaceutical procurement across state health agencies and cooperative purchasing vehicles.